TY - JOUR
T1 - Outcomes in Patients 65 Years or Older Treated with Trimodality Therapy for Esophageal Carcinoma
T2 - 2208
AU - Malik, N.K.
AU - Patil, S.
AU - Groman, A.
AU - Nava, H.
AU - Yendamuri, S.
AU - Nurkin, S.
AU - Sher, T.
AU - Warren, G.
AU - Yang, Gary Y.
AU - May, K.
PY - 2011/10/1
Y1 - 2011/10/1
N2 - Purpose/Objective(s): There is little published information on the results of neoadjuvant chemoradiotherapy (CRT) followed by surgery in older patients due to the presumed increased risk for morbidity and mortality. We report our single institutional experience of trimodality therapy in patients with esophageal carcinoma 65 years of age or older. Materials/Methods: Patients treated with preoperative CRT followed by esophagectomy from 2002-2010 were identified for this IRB approved retrospective study. Patient and treatment characteristics, tolerance, response, and survival were analyzed in patients ≥ 65 years of age versus patients65 years of age, median survival was 35.2 months and 3 and 5 year overall survival rates were 45.9% and 37.1% respectively. Conclusions: These data suggest that older patients can be appropriately selected for neoadjuvant chemoradiotherapy followed by surgery when a comprehensive multidisciplinary approach is utilized. Age alone should not preclude consideration for trimodality therapy in patients with esophageal carcinoma.
AB - Purpose/Objective(s): There is little published information on the results of neoadjuvant chemoradiotherapy (CRT) followed by surgery in older patients due to the presumed increased risk for morbidity and mortality. We report our single institutional experience of trimodality therapy in patients with esophageal carcinoma 65 years of age or older. Materials/Methods: Patients treated with preoperative CRT followed by esophagectomy from 2002-2010 were identified for this IRB approved retrospective study. Patient and treatment characteristics, tolerance, response, and survival were analyzed in patients ≥ 65 years of age versus patients65 years of age, median survival was 35.2 months and 3 and 5 year overall survival rates were 45.9% and 37.1% respectively. Conclusions: These data suggest that older patients can be appropriately selected for neoadjuvant chemoradiotherapy followed by surgery when a comprehensive multidisciplinary approach is utilized. Age alone should not preclude consideration for trimodality therapy in patients with esophageal carcinoma.
UR - http://linkinghub.elsevier.com/retrieve/pii/S0360301611013253
UR - https://www.mendeley.com/catalogue/70dbc064-6b18-3605-b7b9-8fddf860d2e2/
U2 - 10.1016/j.ijrobp.2011.06.504
DO - 10.1016/j.ijrobp.2011.06.504
M3 - Meeting abstract
VL - 81
SP - S312
JO - International Journal of Radiation Oncology Biology Physics
JF - International Journal of Radiation Oncology Biology Physics
IS - 2
ER -